HebeCell Corp Revenue and Competitors

Natick, MA

Location

$63M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • HebeCell Corp's estimated annual revenue is currently $1.9M per year.(i)
  • HebeCell Corp's estimated revenue per employee is $77,500
  • HebeCell Corp's total funding is $63M.

Employee Data

  • HebeCell Corp has 24 Employees.(i)
  • HebeCell Corp grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

HebeCell was founded in 2016 by a group of scientists who wanted to push research in regenerative medicine and immuno-oncology farther than ever before. Our team of researchers includes multiple world-leading experts in stem cell biology, as well as experienced entrepreneurs and business developers. We operate a fully-equipped, state-of-the-art laboratory in Natick, MA, one of the world’s largest biotech hubs. Since 2016, we have grown HebeCell into a leading innovator in our field. Most importantly, we have developed and patented a method of producing allogeneic natural killer (NK) cells indefinitely from induced pluripotent stem cells (iPS cells) by suspending them in a liquid solution within specially engineered bioreactors. No other company or lab has this technology or these capabilities.

keywords:N/A

$63M

Total Funding

24

Number of Employees

$1.9M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HebeCell Corp News

2022-04-06 - HebeCell and Vuja De Sciences Announce Strategic Collaboration

HebeCell Corp, founded in 2016, is primarily engaged in developing universal and cost- effective NK cell therapeutics based on its proprietary...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A260%N/A
#2
$2.7M27-13%N/A
#3
$2.1M2769%N/A
#4
$4.6M270%N/A
#5
$5.1M270%N/A